Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.38 |
| ▸ | SRC | P12931 | 6/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.35 |
| ▸ | FLT1 | P17948 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884015 | 0.93 | EGFR (0.40) | EGFRSRCKDRFLT1ABL1 | |
| SCHEMBL3883318 | 0.92 | EGFR (0.39) | EGFRSRCKDRFLT1ABL1 | |
| SCHEMBL3880153 | 0.91 | EGFR (0.39) | EGFRSRCKDRFLT1ABL1 | |
| SCHEMBL3884236 | 0.89 | EGFR (0.38) | EGFRSRCKDRFLT1ABL1 | |
| SCHEMBL3880451 | 0.87 | EGFR (0.39) | EGFRSRCKDRFLT1ABL1 | |
| SCHEMBL3882523 | 0.86 | EGFR (0.39) | EGFRSRCKDRFLT1ABL1 | |
| SCHEMBL3880080 | 0.85 | EGFR (0.38) | EGFRSRCKDRFLT1ABL1 | |
| SCHEMBL3948070 | 0.85 | EGFR (0.35) | EGFRSRCKDRFLT1ABL1 | |
| SCHEMBL3883356 | 0.83 | MAPT (0.38) | EGFRSRC | |
| SCHEMBL3886602 | 0.83 | EGFR (0.36) | EGFRSRCKDRFLT1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | claimed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | claimed |
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CDK1, CDK17, CDK14 | EGFR 1881/4885SRC 1014/4885KDR 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.